Pilot Study of Perioperative Docetaxel, Oxaliplatin, and 5-Fluorouracil (FLOT) in Gastroesophageal Adenocarcinoma
Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
Gastric or gastroesophageal junction adenocarcinoma is commonly treated with chemotherapy
before and after surgery. The chemotherapy regimen used in our institution, called DCF
(docetaxel,cisplatic, 5-fluorouracil) is active, resulting in tumor reduction and dysphagia
relief. however, it is toxic, causing approximately half of patients severe inflammation of
the mucosa (lining) of the mouth and gut. This results, in turn, in mouth sores, vomiting and
diarrhea. Similar regimen called FLOT (5-FU, oxaliplatin,docetaxel) appears to be at least
equally active, but less toxic.
Our ultimate plan is to perform a randomized comparison of DCF and FLOT. Before embarking
upon this, we are conducting this pilot trial in 10 subjects with the FLOT regimen. If less
than 5 patients develop severe mouth sores, vomiting or diarrhea, plans will be made to
proceed with the next trial, a randomized comparison of DCF and FLOT